Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 13/20 | 0.71 |
| ▸ | CHRM4 | P08173 | 13/20 | 0.71 |
| ▸ | CHRM5 | P08912 | 13/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 13/20 | 0.71 |
| ▸ | CHRM3 | P20309 | 13/20 | 0.71 |
| ▸ | DRD2 | P14416 | 9/20 | 0.71 |
| ▸ | DRD4 | P21917 | 9/20 | 0.71 |
| ▸ | DRD3 | P35462 | 9/20 | 0.71 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.67 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.67 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.67 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.67 |
| ▸ | ACHE | P22303 | 5/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8445224 | 0.93 | CHRM1 (0.74) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL12013902 | 0.89 | ACHE (0.75) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL14601855 | 0.87 | ACHE (0.76) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8442782 | 0.85 | CHRM2 (0.69) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8443141 | 0.85 | CHRM2 (0.68) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8443011 | 0.85 | CHRM1 (0.68) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8442415 | 0.84 | CHRM1 (0.67) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8445194 | 0.82 | CHRM2 (0.64) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8442789 | 0.82 | CHRM1 (0.64) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL9097303 | 0.79 | ACHE (0.64) | CHRM4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021397-A1 | Neurocyte protective agent | EISAI CO., LTD. (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20070021397-A1 | Neurocyte protective agent | EISAI CO., LTD. (JP) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021397-A1 | Neurocyte protective agent | CHAT, GAP43, NES | CHRM2 374/4885CHRM4 355/4885CHRM5 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.